---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pathophysiology"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Pathophysiology. Topics: IL-23/IL-17 axis as the central immune pathway; IL-17 and IL-23 as key drivers identified by immunological and genetic studies; Interplay of T cells, dendritic cells, and keratinocytes; Keratinocyte responses to IL-17: epidermal hyperplasia and leukocyte recruitment; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/pathophysiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### IL-23/IL-17 axis as the central immune pathway

> “Over the last two decades, research has unequivocally shown that psoriasis represents a bona fide T-cell mediated disease primarily driven by pathogenic T-cells that produce high levels of IL-17 in response to IL-23.”
> “Psoriatic disease is, therefore, best understood as a patterned response to chronic activation of the IL-23/T17 pathway.”

Source: [Hawkes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600287/)

<a id="topic-2.2.1.4-2"></a>

### IL-17 and IL-23 as key drivers identified by immunological and genetic studies

> “Immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.4-3"></a>

### Interplay of T cells, dendritic cells, and keratinocytes

> “This suggests a complex interplay between T cells, dendritic cells and keratinocytes as the likely underlying the pathophysiology of psoriasis, with the IL-23/Th17 axis being the central driver of immune activation, chronic inflammation and keratinocyte proliferation.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.4-4"></a>

### Keratinocyte responses to IL-17: epidermal hyperplasia and leukocyte recruitment

> “Epidermal hyperplasia, a hallmark of psoriatic plaques, is associated with STAT3 activation and indirectly regulated by IL-17 through the induction of IL-19 and/or IL-36 by keratinocytes.”
> “IL-17 induces keratinocytes to synthesize and release CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 (i.e. IL-8), which leads to the recruitment of neutrophils and macrophages.”

Source: [Hawkes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600287/)

<a id="topic-2.2.1.4-5"></a>

### TYK2 signaling downstream of IL-12, IL-23, and type I interferon receptors

> “Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis.”
> “Tyrosine kinase 2 (TYK2) is a member of the JAK family of kinases and regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors.”

Source: [Krueger et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34224773/)

<a id="topic-2.2.1.4-6"></a>

### TYK2 partner kinases and STAT proteins by cytokine

> “TYK2 pairs with JAK2 and engages mainly STAT4 to mediate signal transduction of IL-12.”
> “The TYK2/JAK2 heterodimer, acting through STAT1, STAT3, and STAT4, is likewise required for IL-23 signalling, which regulates the differentiation and survival of Th17 cells.”

Source: [Jensen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10589750/)

<a id="topic-2.2.1.4-7"></a>

### Loss-of-function TYK2 variant P1104A: protection against psoriasis and other autoimmune diseases

> “Rs34536443 leads to the substitution of a highly conserved proline residue with an alanine at position 1104 (P1104A) in the kinase domain of the TYK2 protein”
> “In contrast, the rs34536443 minor allele is protective across all of the diseases tested, and surprisingly, its dosage effect shows a previously unrecognized significant departure from additivity”
> “This arises from minor allele homozygosity at the rs34536443 SNP, which drives a near complete loss of TYK2 function and consequently impairs type I IFN, IL-12 and IL-23 signaling.”

Source: [Dendrou et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5737835/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
